Polymer-conjugated glycosylated neublastin
CA 2522364 C · Owner: Biogen Idec Ma, Inc. · Inventors: Sah, Dinah Wen-Yee; Rossomando, Anthony; Pepinsky, Blake R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide wherein: (a) at , least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 16, 2004 and granted December 9, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 16, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 16, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.